Selected research
Industry Research
Recombinant DNA Drug Industry Research Report 2026
Market perspective
The global Recombinant DNA Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Recombinant DNA Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Recombinant DNA Drug market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Recombinant DNA Drug market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Recombinant DNA Drug include GenSci, Takeda, CSPC, 3SBIO, Sandoz, Sanofi, Johnson & Johnson, Novo Nordisk and Merck, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Recombinant DNA Drug market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Recombinant DNA Drug.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Recombinant DNA Drug Market by Company
GenSci
Takeda
CSPC
3SBIO
Sandoz
Sanofi
Johnson & Johnson
Novo Nordisk
Merck
Roche
Eli Lilly
Pfizer
GlaxoSmithKline
Biogen
Bayer
Bristol-Myers Squibb
Amgen
AbbVie
Swedish Orphan Biovitrum
Organon Pharma
Recombinant DNA Drug Segment by Type
Fusion Protein
Recombinant Interleukin
Recombinant Interferon
Recombinant Hormone
Recombinant Coagulation Factor
Recombinant Growth Factor
Other
Recombinant DNA Drug Segment by Application
Infectious Diseases
Metabolic Disorders
Cancers
Autoimmune Diseases
Recombinant DNA Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant DNA Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Recombinant DNA Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant DNA Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Recombinant DNA Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Fusion Protein
- Recombinant Interleukin
- Recombinant Interferon
- Recombinant Hormone
- Recombinant Coagulation Factor
- Recombinant Growth Factor
- Other
Applications
- Infectious Diseases
- Metabolic Disorders
- Cancers
- Autoimmune Diseases
Companies covered
- GenSci
- Takeda
- CSPC
- 3SBIO
- Sandoz
- Sanofi
- Johnson & Johnson
- Novo Nordisk
- Merck
- Roche
- Eli Lilly
- Pfizer
- GlaxoSmithKline
- Biogen
- Bayer
- Bristol-Myers Squibb
- Amgen
- AbbVie
- Swedish Orphan Biovitrum
- Organon Pharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Recombinant DNA Drug by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Fusion Protein
- 2.2.3 Recombinant Interleukin
- 2.2.4 Recombinant Interferon
- 2.2.5 Recombinant Hormone
- 2.2.6 Recombinant Coagulation Factor
- 2.2.7 Recombinant Growth Factor
- 2.2.8 Other
- 2.3 Recombinant DNA Drug by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Infectious Diseases
- 2.3.3 Metabolic Disorders
- 2.3.4 Cancers
- 2.3.5 Autoimmune Diseases
- 2.4 Assumptions and Limitations
3 Recombinant DNA Drug Breakdown Data by Type
- 3.1 Global Recombinant DNA Drug Historic Market Size by Type (2021-2026)
- 3.2 Global Recombinant DNA Drug Forecasted Market Size by Type (2027-2032)
4 Recombinant DNA Drug Breakdown Data by Application
- 4.1 Global Recombinant DNA Drug Historic Market Size by Application (2021-2026)
- 4.2 Global Recombinant DNA Drug Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Recombinant DNA Drug Market Perspective (2021-2032)
- 5.2 Global Recombinant DNA Drug Growth Trends by Region
- 5.2.1 Global Recombinant DNA Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Recombinant DNA Drug Historic Market Size by Region (2021-2026)
- 5.2.3 Recombinant DNA Drug Forecasted Market Size by Region (2027-2032)
- 5.3 Recombinant DNA Drug Market Dynamics
- 5.3.1 Recombinant DNA Drug Industry Trends
- 5.3.2 Recombinant DNA Drug Market Drivers
- 5.3.3 Recombinant DNA Drug Market Challenges
- 5.3.4 Recombinant DNA Drug Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Recombinant DNA Drug Players by Revenue
- 6.1.1 Global Top Recombinant DNA Drug Players by Revenue (2021-2026)
- 6.1.2 Global Recombinant DNA Drug Revenue Market Share by Players (2021-2026)
- 6.2 Global Recombinant DNA Drug Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Recombinant DNA Drug Head Office and Area Served
- 6.4 Global Recombinant DNA Drug Players, Product Type & Application
- 6.5 Global Recombinant DNA Drug Manufacturers Established Date
- 6.6 Global Recombinant DNA Drug Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Recombinant DNA Drug Market Size (2021-2032)
- 7.2 North America Recombinant DNA Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Recombinant DNA Drug Market Size by Country (2021-2026)
- 7.4 North America Recombinant DNA Drug Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Recombinant DNA Drug Market Size (2021-2032)
- 8.2 Europe Recombinant DNA Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Recombinant DNA Drug Market Size by Country (2021-2026)
- 8.4 Europe Recombinant DNA Drug Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Recombinant DNA Drug Market Size (2021-2032)
- 9.2 Asia-Pacific Recombinant DNA Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Recombinant DNA Drug Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Recombinant DNA Drug Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Recombinant DNA Drug Market Size (2021-2032)
- 10.2 South America Recombinant DNA Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Recombinant DNA Drug Market Size by Country (2021-2026)
- 10.4 South America Recombinant DNA Drug Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Recombinant DNA Drug Market Size (2021-2032)
- 11.2 Middle East & Africa Recombinant DNA Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Recombinant DNA Drug Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Recombinant DNA Drug Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 GenSci
- 12.1.1 GenSci Company Information
- 12.1.2 GenSci Business Overview
- 12.1.3 GenSci Revenue in Recombinant DNA Drug Business (2021-2026)
- 12.1.4 GenSci Recombinant DNA Drug Product Portfolio
- 12.1.5 GenSci Recent Developments
- 12.2 Takeda
- 12.2.1 Takeda Company Information
- 12.2.2 Takeda Business Overview
- 12.2.3 Takeda Revenue in Recombinant DNA Drug Business (2021-2026)
- 12.2.4 Takeda Recombinant DNA Drug Product Portfolio
- 12.2.5 Takeda Recent Developments
- 12.3 CSPC
- 12.3.1 CSPC Company Information
- 12.3.2 CSPC Business Overview
- 12.3.3 CSPC Revenue in Recombinant DNA Drug Business (2021-2026)
- 12.3.4 CSPC Recombinant DNA Drug Product Portfolio
- 12.3.5 CSPC Recent Developments
- 12.4 3SBIO
- 12.4.1 3SBIO Company Information
- 12.4.2 3SBIO Business Overview
- 12.4.3 3SBIO Revenue in Recombinant DNA Drug Business (2021-2026)
- 12.4.4 3SBIO Recombinant DNA Drug Product Portfolio
- 12.4.5 3SBIO Recent Developments
- 12.5 Sandoz
- 12.5.1 Sandoz Company Information
- 12.5.2 Sandoz Business Overview
- 12.5.3 Sandoz Revenue in Recombinant DNA Drug Business (2021-2026)
- 12.5.4 Sandoz Recombinant DNA Drug Product Portfolio
- 12.5.5 Sandoz Recent Developments
- 12.6 Sanofi
- 12.6.1 Sanofi Company Information
- 12.6.2 Sanofi Business Overview
- 12.6.3 Sanofi Revenue in Recombinant DNA Drug Business (2021-2026)
- 12.6.4 Sanofi Recombinant DNA Drug Product Portfolio
- 12.6.5 Sanofi Recent Developments
- 12.7 Johnson & Johnson
- 12.7.1 Johnson & Johnson Company Information
- 12.7.2 Johnson & Johnson Business Overview
- 12.7.3 Johnson & Johnson Revenue in Recombinant DNA Drug Business (2021-2026)
- 12.7.4 Johnson & Johnson Recombinant DNA Drug Product Portfolio
- 12.7.5 Johnson & Johnson Recent Developments
- 12.8 Novo Nordisk
- 12.8.1 Novo Nordisk Company Information
- 12.8.2 Novo Nordisk Business Overview
- 12.8.3 Novo Nordisk Revenue in Recombinant DNA Drug Business (2021-2026)
- 12.8.4 Novo Nordisk Recombinant DNA Drug Product Portfolio
- 12.8.5 Novo Nordisk Recent Developments
- 12.9 Merck
- 12.9.1 Merck Company Information
- 12.9.2 Merck Business Overview
- 12.9.3 Merck Revenue in Recombinant DNA Drug Business (2021-2026)
- 12.9.4 Merck Recombinant DNA Drug Product Portfolio
- 12.9.5 Merck Recent Developments
- 12.10 Roche
- 12.10.1 Roche Company Information
- 12.10.2 Roche Business Overview
- 12.10.3 Roche Revenue in Recombinant DNA Drug Business (2021-2026)
- 12.10.4 Roche Recombinant DNA Drug Product Portfolio
- 12.10.5 Roche Recent Developments
- 12.11 Eli Lilly
- 12.11.1 Eli Lilly Company Information
- 12.11.2 Eli Lilly Business Overview
- 12.11.3 Eli Lilly Revenue in Recombinant DNA Drug Business (2021-2026)
- 12.11.4 Eli Lilly Recombinant DNA Drug Product Portfolio
- 12.11.5 Eli Lilly Recent Developments
- 12.12 Pfizer
- 12.12.1 Pfizer Company Information
- 12.12.2 Pfizer Business Overview
- 12.12.3 Pfizer Revenue in Recombinant DNA Drug Business (2021-2026)
- 12.12.4 Pfizer Recombinant DNA Drug Product Portfolio
- 12.12.5 Pfizer Recent Developments
- 12.13 GlaxoSmithKline
- 12.13.1 GlaxoSmithKline Company Information
- 12.13.2 GlaxoSmithKline Business Overview
- 12.13.3 GlaxoSmithKline Revenue in Recombinant DNA Drug Business (2021-2026)
- 12.13.4 GlaxoSmithKline Recombinant DNA Drug Product Portfolio
- 12.13.5 GlaxoSmithKline Recent Developments
- 12.14 Biogen
- 12.14.1 Biogen Company Information
- 12.14.2 Biogen Business Overview
- 12.14.3 Biogen Revenue in Recombinant DNA Drug Business (2021-2026)
- 12.14.4 Biogen Recombinant DNA Drug Product Portfolio
- 12.14.5 Biogen Recent Developments
- 12.15 Bayer
- 12.15.1 Bayer Company Information
- 12.15.2 Bayer Business Overview
- 12.15.3 Bayer Revenue in Recombinant DNA Drug Business (2021-2026)
- 12.15.4 Bayer Recombinant DNA Drug Product Portfolio
- 12.15.5 Bayer Recent Developments
- 12.16 Bristol-Myers Squibb
- 12.16.1 Bristol-Myers Squibb Company Information
- 12.16.2 Bristol-Myers Squibb Business Overview
- 12.16.3 Bristol-Myers Squibb Revenue in Recombinant DNA Drug Business (2021-2026)
- 12.16.4 Bristol-Myers Squibb Recombinant DNA Drug Product Portfolio
- 12.16.5 Bristol-Myers Squibb Recent Developments
- 12.17 Amgen
- 12.17.1 Amgen Company Information
- 12.17.2 Amgen Business Overview
- 12.17.3 Amgen Revenue in Recombinant DNA Drug Business (2021-2026)
- 12.17.4 Amgen Recombinant DNA Drug Product Portfolio
- 12.17.5 Amgen Recent Developments
- 12.18 AbbVie
- 12.18.1 AbbVie Company Information
- 12.18.2 AbbVie Business Overview
- 12.18.3 AbbVie Revenue in Recombinant DNA Drug Business (2021-2026)
- 12.18.4 AbbVie Recombinant DNA Drug Product Portfolio
- 12.18.5 AbbVie Recent Developments
- 12.19 Swedish Orphan Biovitrum
- 12.19.1 Swedish Orphan Biovitrum Company Information
- 12.19.2 Swedish Orphan Biovitrum Business Overview
- 12.19.3 Swedish Orphan Biovitrum Revenue in Recombinant DNA Drug Business (2021-2026)
- 12.19.4 Swedish Orphan Biovitrum Recombinant DNA Drug Product Portfolio
- 12.19.5 Swedish Orphan Biovitrum Recent Developments
- 12.20 Organon Pharma
- 12.20.1 Organon Pharma Company Information
- 12.20.2 Organon Pharma Business Overview
- 12.20.3 Organon Pharma Revenue in Recombinant DNA Drug Business (2021-2026)
- 12.20.4 Organon Pharma Recombinant DNA Drug Product Portfolio
- 12.20.5 Organon Pharma Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst